Bradmer to participate in panel presentation at RBC Capital Markets Healthcare ... ( TSX: BMR TORONTO Dec. 9 / ...)

Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference

Date:12/9/2008

TSX: BMR

TORONTO, Dec. 9 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that Alan M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer will be presenting as a panel participant at the 2008 RBC Capital Markets Healthcare Conference, held at the Westin Times Square Hotel in New York City. The panel titled, Antibody Strategies For Fighting Cancer, is scheduled from 3:30 pm to 4:25 pm (Eastern Time) on December 10, 2008 in Panel Room 2. Interested parties can access a live audio webcast of the panel by visiting Bradmer's website at www.bradmerpharma.com. The webcast will be available for 30 days after the conference.

About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)

Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab(R), was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. Bradmer has initiated enrollment in a Phase III multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemp
'/>"/>

0

GOOD

Page: 1 2
Related medicine news :

1. Bradmer announces management changes
2. Bradmer provides Phase III Neuradiab trial update and guidance
3. Bradmer to present at Rodman & Renshaw Healthcare Conference
4. Bradmer Medical Isotope Supply For Phase III Trial Secure
5. Bradmer announces additions to Scientific Advisory Board
6. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
7. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
8. Notice of Bradmer Pharmaceuticals Conference Call
9. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
10. Bradmer announces new additions to management team
11. Bradmer announces 2008 first quarter operational and financial results

Post Your Comments:

Bradmer to participate in panel presentation at RBC Capital Markets Healthcare ...( TSX: BMR TORONTO Dec. 9 / ...),Health